Statutory Rules 1986 No. 3201

National Health (Pharmaceutical Benefits)

Regulations2 (Amendment)

WHEREAS it is provided by sub-section 101 (4) of the National Health Act 1953 that a drug or medicinal preparation that was not a pharmaceutical benefit under that Act immediately before the commencement of that subsection shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that each of the following drugs or medicinal preparations be prescribed as a pharmaceutical benefit under section 85 of that Act, namely—

(a) Indapamide;

(b) Insulin Neutral, Human (Synthetic);

(c) Insulin Zinc Suspension, Human (Synthetic);

(d) Insulin Zinc Suspension (Crystalline), Human (Synthetic);

(e) Oestrogens—Conjugated;

(f) Piroxicam;

(g) Polygeline; and

(h) Silver Sulphadiazine:

AND WHEREAS it is desirable, amongst other things, to prescribe each of those drugs or medicinal preparations as a pharmaceutical benefit under that section:

NOW THEREFORE I, the Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953.

Dated 29 OCTOBER 1986.

N. M. STEPHEN

Governor-General

By His Excellency’s Command,

Neal Blewett

Minister of State for Health

(S.R. 317/86)—Cat. No.            8/20.10.1986

Commencement

1. These Regulations shall come into operation on 1 November 1986.

Principal Regulations

2. In these Regulations, “Principal Regulations” means the National Health (Pharmaceutical Benefits) Regulations.

Schedule 1

3. Schedule 1 to the Principal Regulations is amended as set out in Schedule 1.

Schedule 2

4. Schedule 2 to the Principal Regulations is amended as set out in Schedule 2.

Schedule 3

5. Schedule 3 to the Principal Regulations is amended as set out in Schedule 3.

Schedule 4

6. Schedule 4 to the Principal Regulations is amended as set out in Schedule 4.

Schedule 5

7. Schedule 5 to the Principal Regulations is amended as set out in Schedule 5.

SCHEDULE 1    Regulation 3

AMENDMENTS OF SCHEDULE 1 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. After item 17 insert the following item:

“17a Aloxiprin Tablets”.

2. After item 72 insert the following item:

“72a Ascorbic Acid Tablets”.

3. After item 75 insert the following items:

“75a Aspirin Tablets

75b Aspirin Tablets, Dispersible”.

4. After item 185 insert the following item:

“185a Carbenicillin Sodium”.

5. After item 254 insert the following item:

“254a Chlorpheniramine Tablets”.

6. After item 342 insert the following items:

“342a Dextromoramide Tablets

342b Dextromoramide Tartrate”.

7. After item 381 insert the following item:

“381a Dihydrocodeine Tartrate”.

SCHEDULE 1—continued

8. After item 393 insert the following items:

“393a Diphenhydramine Capsules

393b Diphenhydramine Elixir

393c Diphenylpyraline Hydrochloride”.

9. After item 555 insert the following item:

“555a Guanethidine Tablets”.

10. After item 583 insert the following item:

“583a Hydrogen Peroxide Solution (3 per cent)”.

11. After item 631 insert the following item:

“631a Isoprenaline Hydrochloride”.

12. After item 692 insert the following item:

“692a Magnesium Sulphate, Dried”.

13. After item 706 insert the following item:

“706a Meclozine Tablets”.

14. After item 836 insert the following item:

“836a Oxytetracycline Capsules”.

15. After item 848 insert the following item:

“848a Paracetamol Tablets”.

16. After item 887 insert the following item:

“887a Pheniramine Maleate”.

17. After item 910 insert the following item:

“910a Pholcodine”.

18. Omit item 957.

19. After item 985 insert the following items:

“985a Promethazine Hydrochloride Elixir 985B Promethazine Hydrochloride Tablets”.

20. After item 1028 insert the following item:

“1028a Riboflavine”.

21. After item 1103 insert the following item:

“1 103a Sodium Valproate Tablets”.

22. After item 1115 insert the following item:

“1115a Squill Elixir”.

23. After item 1246 insert the following item:

“1246a Trimeprazine Tablets”.

SCHEDULE 2    Regulation 4

AMENDMENTS OF SCHEDULE 2 TO THE                                                         NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 22.

2. Omit item 26.

3. Omit item 41.

4. Omit item 48.

5. After item 58 insert the following item:

“58a Chloroquine Sulphate, B.P. —”.

6. Omit item 67.

7. Omit item 84.

8. Omit item 87.

SCHEDULE 2—continued

     SCHEDULE 3     Regulation 5

AMENDMENTS OF SCHEDULE 3 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 28.

2. Omit item 32.

3. Omit item 42.

4. Omit item 53.

SCHEDULE 3—continued

5. Omit item 70.

6. Omit item 79.

7. Omit item 96.

8. Omit item 106.

9. Omit item 113.

10. After item 122 insert the following item:

“122a Indapamide”.

11. Omit item 130.

12. After item 131 insert the following items:

“131a Insulin Neutral, Human (Synthetic)

131b Insulin Zinc Suspension, Human (Synthetic)

131c Insulin Zinc Suspension (Crystalline), Human (Synthetic)”.

13. After item 178 insert the following item:

“178a Oestrogens—Conjugated”.

14. Omit item 191.

15. After item 196 insert the following item:

“196a Piroxicam”.

16. After item 204 insert the following item:

“204a Polygeline”.

17. Omit item 227.

18. Omit item 229.

19. After item 230 insert the following item:

“230a Silver Sulphadiazine”.

SCHEDULE 4   Regulation 6

AMENDMENT OF SCHEDULE 4 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 16.

SCHEDULE 5   Regulation 7

AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

SCHEDULE 5—continued

SCHEDULE 5—continued

SCHEDULE 5—continued

NOTES

1. Notified in the Commonwealth of Australia Gazette on 31 October 1986.

Printed by Authority by the Commonwealth Government Printer